Sensus Healthcare, Inc. (NASDAQ:SRTS) Given Average Rating of “Moderate Buy” by Brokerages

Sensus Healthcare, Inc. (NASDAQ:SRTS) has been given a consensus recommendation of “Moderate Buy” by the six analysts that are currently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating on the company. The average 1-year price target among brokers that have covered the stock in the last year is $5.8333.

A number of equities analysts recently weighed in on the company. Weiss Ratings cut Sensus Healthcare from a “sell (d)” rating to a “sell (d-)” rating in a report on Tuesday, August 18th. Alliance Global Partners restated a “buy” rating on shares of Sensus Healthcare in a research report on Monday, August 17th. Finally, Lake Street Capital decreased their target price on Sensus Healthcare from $4.50 to $4.00 and set a “buy” rating on the stock in a research report on Friday, August 14th.

Sensus Healthcare Stock Performance

SRTS stock opened at $3.12 on Friday. Sensus Healthcare has a one year low of $2.66 and a one year high of $5.49. The firm’s fifty day moving average is $3.11 and its 200 day moving average is $3.43. The firm has a market cap of $51.36 million, a PE ratio of -3.32 and a beta of 1.13.

Sensus Healthcare (NASDAQ:SRTS) last issued its quarterly earnings data on Thursday, August 13th. The company reported ($0.53) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.41). Sensus Healthcare had a negative return on equity of 21.57% and a negative net margin of 88.45%.The firm had revenue of $2.29 million during the quarter, compared to analyst estimates of $4.60 million.

Insiders Place Their Bets

In related news, Director Eric Sachetta acquired 37,537 shares of the firm’s stock in a transaction on Friday, August 28th. The shares were acquired at an average cost of $3.44 per share, with a total value of $129,127.28. Following the completion of the acquisition, the director directly owned 267,480 shares in the company, valued at approximately $920,131.20. This trade represents a 16.32% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders have acquired 120,171 shares of company stock worth $405,230 in the last ninety days. Corporate insiders own 10.20% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. BlackRock Inc. purchased a new position in shares of Sensus Healthcare in the second quarter valued at approximately $252,000. Bank of New York Mellon Corp purchased a new position in Sensus Healthcare in the 2nd quarter valued at $303,000. EP Wealth Advisors LLC acquired a new stake in Sensus Healthcare during the 2nd quarter worth $49,000. Finally, North Star Investment Management Corp. purchased a new stake in shares of Sensus Healthcare during the first quarter worth $500,000. 25.30% of the stock is owned by hedge funds and other institutional investors.

About Sensus Healthcare

Sensus Healthcare, Inc is a medical device company focused on noninvasive treatments for dermatologic and oncologic conditions. The company develops and commercializes superficial radiation therapy systems designed to deliver low-energy X-rays to targeted areas of the skin while limiting exposure to surrounding tissue.

Its principal products include the SRT-100 and SRT-100 Vision systems, which are used primarily to treat non-melanoma skin cancers such as basal cell and squamous cell carcinomas, as well as certain keloid scars.